Jevtana (cabazitaxel) is a chemotherapy drug used to treat prostate cancer, a disease that occurs when cells in the prostate start to grow out of control. The prostate is a gland that is sized and shaped like a walnut, which is found in a man’s reproductive system and located below the bladder, near the rectum and around the urethra. Due to the location of the gland, prostate cancer affects both the reproductive and urinary systems.

Other than skin cancer, prostate cancer is the most common type of cancer among American men, with about 180,890 new cases diagnosed, and 26,120 resulting deaths every year, according to American Cancer Society estimates. Prostate cancer is particularly rare among younger men, while the average age of diagnosis is 66 years. About one in every seven men will be diagnosed with prostate cancer.

How cabazitaxel works

Jevtana (cabazitaxel) is classified as a taxane chemotherapy drug and a microtubule inhibitor. The course of action of these types of treatments is based on stopping the cancerous cells from diving into new cells, which then blocks the growth of the cancer. It is currently used for the treatment of advanced prostate cancer, but its use is currently being investigated in other types of cancer as well.

 The compound was approved by the U.S. Food and Drug Administration (FDA) in 2010. The approval was based mainly on the results of a clinical trial of 755 patients with [castrate resistant metastatic prostate cancer] previously treated with docetaxel, according to the National Institutes of Health.

Cabazitaxel to treat prostate cancer

Jevtana is prescribed in combination with prednisone for the treatment of castrate resistant metastatic prostate cancer who were previously treated with a docetaxel-containing regimen. Patients are administered Jevtana intravenously. The treatment is recommended every three weeks and usually includes daily steroids as tablets.

“Cabazitaxel is a novel tubulin-binding taxane drug with antitumor activity in docetaxel-resistant cancers,” wrote the authors of the study “Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.”

“Treatment with cabazitaxel plus prednisone has important clinical antitumor activity, improving overall survival in patients with metastatic castration-resistant prostate cancer whose disease has progressed during or after docetaxel-based therapy.”

Note: Prostate Cancer News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.